Anaplastic large cell lymphoma risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2], Kamal Akbar, M.D.[3]

Overview

There are no established risk factors for anaplastic large cell lymphoma.

Risk Factors

There are no real established risk factors for anaplastic large cell lymphoma, but the following are some known predisposing factors:^[1]^[2]
- Male predominance
- 2;5 translocation in the sub-types of Anaplastic large cell lymphoma
- Textured breast implants (also know as breast implant associated anaplastic large cell lymphoma)^[3]^[4]^[5]^[6]

References

↑ Mereu E, Pellegrino E, Scarfò I, Inghirami G, Piva R (2017). “The heterogeneous landscape of ALK negative ALCL”. Oncotarget. 8 (11): 18525–18536. doi:10.18632/oncotarget.14503. PMC 5392347. PMID 28061468.
↑ Cao S, Nambudiri VE (2017). “Anaplastic Lymphoma Kinase in Cutaneous Malignancies”. Cancers (Basel). 9 (9). doi:10.3390/cancers9090123. PMC 5615338. PMID 28895885.
↑ Clemens MW, Nava MB, Rocco N, Miranda RN (2017). “Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules”. Gland Surg. 6 (2): 169–184. doi:10.21037/gs.2016.11.03. PMC 5409903. PMID 28497021.
↑ Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S; et al. (2016). “Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma”. J Clin Oncol. 34 (2): 160–8. doi:10.1200/JCO.2015.63.3412. PMC 4872006. PMID 26628470.
↑ Kricheldorff J, Fallenberg EM, Solbach C, Gerber-Schäfer C, Rancsó C, Fritschen UV (2018). “Breast Implant-Associated Lymphoma”. Dtsch Arztebl Int. 115 (38): 628–635. doi:10.3238/arztebl.2018.0628. PMC 6218708. PMID 30373708.
↑ Di Napoli A, Pepe G, Giarnieri E, Cippitelli C, Bonifacino A, Mattei M; et al. (2017). “Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma”. PLoS One. 12 (7): e0181097. doi:10.1371/journal.pone.0181097. PMC 5513491. PMID 28715445.

Template:WH Template:WS

[pmid28061468-1] Mereu E, Pellegrino E, Scarfò I, Inghirami G, Piva R (2017). “The heterogeneous landscape of ALK negative ALCL”. Oncotarget. 8 (11): 18525–18536. doi:10.18632/oncotarget.14503. PMC 5392347. PMID 28061468.

[pmid28895885-2] Cao S, Nambudiri VE (2017). “Anaplastic Lymphoma Kinase in Cutaneous Malignancies”. Cancers (Basel). 9 (9). doi:10.3390/cancers9090123. PMC 5615338. PMID 28895885.

[pmid28497021-3] Clemens MW, Nava MB, Rocco N, Miranda RN (2017). “Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules”. Gland Surg. 6 (2): 169–184. doi:10.21037/gs.2016.11.03. PMC 5409903. PMID 28497021.

[pmid26628470-4] Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S; et al. (2016). “Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma”. J Clin Oncol. 34 (2): 160–8. doi:10.1200/JCO.2015.63.3412. PMC 4872006. PMID 26628470.

[pmid30373708-5] Kricheldorff J, Fallenberg EM, Solbach C, Gerber-Schäfer C, Rancsó C, Fritschen UV (2018). “Breast Implant-Associated Lymphoma”. Dtsch Arztebl Int. 115 (38): 628–635. doi:10.3238/arztebl.2018.0628. PMC 6218708. PMID 30373708.

[pmid28715445-6] Di Napoli A, Pepe G, Giarnieri E, Cippitelli C, Bonifacino A, Mattei M; et al. (2017). “Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma”. PLoS One. 12 (7): e0181097. doi:10.1371/journal.pone.0181097. PMC 5513491. PMID 28715445.

[1]

[2]

[3]

[4]

[5]

[6]